Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer

NCT04501497 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT04501497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Patients With Unresectable, Advanced and Recurrent Non-small Cell Lung Cancer or Extensive Disease Small Cell Lung Cancer
Lead sponsor
Chugai Pharmaceutical
Phase
Observational
Overall status
Completed
Start date
August 21, 2020
Completion date
February 3, 2023
Enrollment
1,221 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

extensive disease small cell lung cancer, non-small cell lung cancer